Duncan Kimberly J, Eckert Kristin A, Clawson Gary A
Jake Gittlen Cancer Research Foundation, Pennsylvania State University College of Medicine, 500 University Drive, Hershey, PA 17033, USA.
J Pharmacol Exp Ther. 2009 Jul;330(1):359-66. doi: 10.1124/jpet.108.149765. Epub 2009 Apr 28.
The chymotrypsin-like serine protease inhibitor, succinyl-alanine-alanine-proline-phenylalanine chloromethyl ketone (AAPF(CMK)), has been shown to have anticarcinogenic activity in a number of model systems and to be relatively selective for a nuclear protease. This inhibitor also has substantial effects on growth of tumorigenic human papillomavirus (HPV)-infected keratinocytes in organotypic raft cultures. Here, we examined the effects of AAPF(CMK) on cell growth, cell-cycle kinetics, apoptosis induction, and DNA synthesis in two human cervical carcinoma cell lines: SiHa cells, which have integrated high-risk HPV-16; and C33a cells, which do not contain HPV DNA. AAPF(CMK) inhibited growth of both cell lines in a time- and dose-dependent manner. Apoptosis studies showed no significant difference in drug-treated versus vehicle-treated cells in the C33a cell line. However, a significant dose-dependent increase in apoptosis occurred at a late time point in SiHa cells. Cell-cycle progression and DNA synthesis assays showed that the cellular mechanisms of growth inhibition by AAPF(CMK) differ between the HPV16-positive and HPV-negative tumorigenic cell lines. Drug-treated C33a cells showed a significant accumulation of cells in the G(2) phase of the cell cycle. In SiHa cells, growth inhibition produced by AAPF(CMK) seemed to result from a global arrest of the cell cycle. Although the molecular mechanisms involved in AAPF(CMK)-induced growth inhibition are distinct between the two tumorigenic cell lines, such differences may ultimately prove to have therapeutic utility. Novel therapies for treating established HPV infections are needed, because HPV is a causative agent in the development of multiple types of cancer.
类胰凝乳蛋白酶样丝氨酸蛋白酶抑制剂琥珀酰 - 丙氨酸 - 丙氨酸 - 脯氨酸 - 苯丙氨酸氯甲基酮(AAPF(CMK))已被证明在许多模型系统中具有抗癌活性,并且对一种核蛋白酶具有相对选择性。该抑制剂对器官型浮膜培养中致瘤性人乳头瘤病毒(HPV)感染的角质形成细胞的生长也有显著影响。在此,我们研究了AAPF(CMK)对两种人宫颈癌细胞系细胞生长、细胞周期动力学、凋亡诱导和DNA合成的影响:SiHa细胞,其整合了高危HPV - 16;以及C33a细胞,其不含HPV DNA。AAPF(CMK)以时间和剂量依赖性方式抑制两种细胞系的生长。凋亡研究表明,在C33a细胞系中,药物处理组与溶剂处理组细胞之间无显著差异。然而,在SiHa细胞中,在较晚时间点出现了显著的剂量依赖性凋亡增加。细胞周期进程和DNA合成分析表明,AAPF(CMK)抑制生长的细胞机制在HPV16阳性和HPV阴性致瘤细胞系之间有所不同。药物处理的C33a细胞在细胞周期的G(2)期出现显著的细胞积累。在SiHa细胞中,AAPF(CMK)产生的生长抑制似乎是由于细胞周期的整体停滞。尽管AAPF(CMK)诱导生长抑制所涉及的分子机制在两种致瘤细胞系中不同,但这种差异最终可能证明具有治疗效用。由于HPV是多种癌症发生发展的致病因素,因此需要治疗已确诊HPV感染的新疗法。